Eculizumab for the treatment of myasthenia gravis

References

• Vincent A, Huda S, Cao M, et al. Serological and experimental studies in different forms of myasthenia gravis. Ann N Y Acad Sci. 2018;1413:143–153.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5:30.
   PubMed Web of Science ®Google Scholar
• Kerty E, Elsais A, Argov Z, et al. EFNS/ENS guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21:687–693.
   PubMed Web of Science ®Google Scholar
• Hehir MK, Silvestri NJ. Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 2018;36:253–260.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang W, Li J. Evaluation of serum IgG subclass concentrations in myasthenia gravis patients. Int J Neurosci. 2011;121(10):570–574.
   PubMed Web of Science ®Google Scholar
• Tuzun E, Scott BG, Goluszko E, et al. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol. 2003;171:3847–3854.
   PubMed Web of Science ®Google Scholar
• Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116:2843–2854.
   PubMed Web of Science ®Google Scholar
• Tuzun E, Christadoss P. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev. 2013;12:904–911.
   PubMed Web of Science ®Google Scholar
• Shen CY, Lu Y, Zhang B, et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest. 2013;123:5190–5202.
   PubMed Web of Science ®Google Scholar
• Huijbers MG, Zhang W, Klooster R, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci USA. 2013;110:20783–20788.
   PubMed Web of Science ®Google Scholar
• Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46.
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Cavalcante P. Diagnosis and treatment of myasthenia gravis. Curr Opin Rheumatol. 2019;31:623–633.
   PubMed Web of Science ®Google Scholar
• Cron MA, Maillard S, Villegas J, et al. Thymus involvement in early-onset myasthenia gravis. Ann N Y Acad Sci. 2018;1412:137–145.
   PubMed Web of Science ®Google Scholar
• Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87:419–425.
   PubMed Web of Science ®Google Scholar
• Sanders DB, Wolfe GI, Narayanaswami P. MGFA task force on MG treatment guidance. Developing treatment guidelines for myasthenia gravis. Ann N Y Acad Sci. 2018;1412:95–101.
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Bonanno S, Camera G, et al. Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat. 2011;7:151–160.
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Kaminski HJ, Aban Minisman IB, et al. MGTX study group. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375:511–522.
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Kaminski HJ, Aban IB, et al. MGTX Study Group. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019;18:259–268.
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134.
   Web of Science ®Google Scholar
• Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013;86:255–260.
   PubMedGoogle Scholar
• Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014;15:167–178.
   PubMedGoogle Scholar
• Hewett K, Sanders DB, Grove RA, et al. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90:e1425–e1434.
   PubMed Web of Science ®Google Scholar
• Howard JF Jr, Bril V, Burns TM, et al. Efgartigimod MG study group. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravi. Neurology. 2019;92:e2661–e2673.
   PubMed Web of Science ®Google Scholar
• Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16:976–986.
   PubMed Web of Science ®Google Scholar
• Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60:14–24.
   PubMed Web of Science ®Google Scholar
• Howard JF Jr, Nowak RJ, Wolfe GI, et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 2020 Feb 17;77(5):582..
   Web of Science ®Google Scholar
• Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single chain Fv. Mol Immunol. 1996;33:1389–1401.
   PubMed Web of Science ®Google Scholar
• Wijnsma KL, Heine RT, Moes DJAR, et al. Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet. 2019;58:859–874.
   PubMed Web of Science ®Google Scholar
• Merle NS, Church SE, Fremeaux-Bacch V, et al. Complement system part i – molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
   PubMed Web of Science ®Google Scholar
• Dmytrijuk A, Robie-Suh K, Cohen MH, et al. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 2008;13:993–1000.
   PubMed Web of Science ®Google Scholar
• C M L, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–2181.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614–625.
   PubMed Web of Science ®Google Scholar
• Alexion Europe SAS. Soliris (eculizumab): summary of product characteristics. 2017. [cited 2020 Mar 30]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000791/WC500054208.pdf
   Google Scholar
• European Medicines Agency (EMA). Soliris: EPAR—scientific discussion. London: EMA; 2007.
   Google Scholar
• Willrich MAV, Andreguetto BD, Sridharan M, et al. The impact of eculizumab on routine complement assays. J Immunol Methods. 2018;460:63–71.
   PubMed Web of Science ®Google Scholar
• Nishimura JI, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370:632–639.
   PubMed Web of Science ®Google Scholar
• Lathia C, Gao X, Kassir N, et al. Population pharmacokinetic and pharmacodynamic analysis of eculizumab to support phase III dosing regimen in patients with refractory generalized myasthenia gravis. Clin Pharmacol Ther. 2015;97(Suppl 1):S87.
   Google Scholar
• Alexion Pharmaceuticals Inc. Soliris (eculizumab): US prescribing information. 2015. [cited 2020 Mar 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125166s422lbl.pdf
   Google Scholar
• Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48:76–84.
   PubMed Web of Science ®Google Scholar
• RHP DM, Verschuuren JJGM, Tannemaat MR. Distinct representation of muscle weakness in QMG and MG-ADL. Lancet Neurol. 2018;17:204–205.
   Web of Science ®Google Scholar
• Andersen H, Mantegazza R, Wang JJ, et al. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019;28:2247–2254.
   PubMed Web of Science ®Google Scholar
• Vissing J, Jacob S, Fujita KP, et al. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020 Mar 18. DOI:10.1007/s00415-020-09770-y.
   Web of Science ®Google Scholar
• Japan Ministry of Health Labour and Welfare. Soliris (eculizumab): Japanese prescribing information. 2017. [cited 2020 Mar 30]. Available from: https://www.businesswire.com/news/home/20171226005046/en/Soliris%C2%AE-Eculizumab-Receives-Marketing-Authorization-Japan-Treatment
   Google Scholar
• Murai H, Uzawa A, Suzuki Y, et al. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. J Neurol Sci. 2019;407:116419.
   PubMed Web of Science ®Google Scholar
• Gilhus NE. Eculizumab: a treatment option for myasthenia gravis? Lancet Neurol. 2017;16:947–948.
   PubMed Web of Science ®Google Scholar